A refined human linear B cell epitope map of Outer surface protein C (OspC) from the Lyme disease spirochete, Borreliella burgdorferi

Abstract

A detailed understanding of the human antibody response to Outer surface protein C (OspC) of Borrelellia burgdorferi has important implications for Lyme disease diagnostics and vaccines. In this report, a total of 13 peptides encompassing eight reported OspC linear B cell epitopes from OspC types A, B and K, including the conserved C-terminus (residues 193-210: peptide C10), were evaluated by multiplex immunoassay (MIA) for IgG reactivity with [~]700 human serum samples confirmed positive in a two-tiered Lyme disease diagnostic assay and [~]160 post-treatment Lyme disease (PTLD) serum samples. The VlsE C6-17 peptide was included as a positive control. Diagnostic serum IgG reacted with 11 of the 13 OspC-derived peptides, significantly more than controls, with the C10 peptide being the most reactive. In the PTLD serum samples, two OspC peptides including C10 were significantly more reactive than controls. Spearmans rank correlation matrices and hierarchical clustering indicated a strong correlation between C10 and VlsE C6-17 peptide reactivity but little demonstrable association between C10 and the other OspC peptides or recombinant OspC. OspC peptide reactivities (excluding C10) were strongly correlated with each other and were disproportionately influenced by a subset of pan-reactive samples. In the PTLD cohort, C10 clustered with the other OspC-derived peptides and was distinct from OspC and VlsE C6-17. The asynchronous serologic response to OspC, C10, and the OspC-derived peptides reveals the complexity of B cell responses to B. burgdorferi and confounds simple interpretation of antibody profiles associated with Lyme disease. IMPORTANCELyme disease is an emerging tick-borne infection caused by the spirochete, Borreliella burgdorferi. In humans, antibodies against spirochetal outer surface lipoproteins are proposed to play a role in disease resolution and in protection against reinfection. Some of those same antibodies also serve as diagnostic indicators of an active or history of Lyme disease. In this study, we sought to validate reported antibody binding sites on Outer surface protein C (OspC), a known target of both protective and diagnostic antibodies.